FDA Approves Caplyta (lumateperone) as an Adjunctive Therapy for the Treatment of Major Depressive Disorder (MDD) in Adults

Nov 7, 2025 - 14:00
 0  1
TITUSVILLE, N.J. (NOVEMBER 6, 2025) – Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved Caplyta® (lumateperone) as an adjunctive therapy with antidepressants for the treatment of...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0